Clinical Trials Logo

Nonalcoholic Steatohepatitis clinical trials

View clinical trials related to Nonalcoholic Steatohepatitis.

Filter by:

NCT ID: NCT03656744 Completed - NAFLD Clinical Trials

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Start date: November 26, 2018
Phase: Phase 2
Study type: Interventional

Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.

NCT ID: NCT03602573 Recruiting - Menopause Clinical Trials

Liver Fibrosis in Peri-menopausal Women

Start date: August 1, 2018
Phase:
Study type: Observational

This is a prospective observational study in a single medical center. The aim is to evaluate the status of fibrosis and steatosis of liver parenchyma in peri-menopausal women using noninvasive methods of vibration-controlled transient elastography (VCTE) with controlled attenuation parameter (CAP) and serum biomarkers. Recruitment period: 2018/08/01 to 2019/07/31 Patient number: 200 females Inclusion criteria: 1. Females, age of 46-55 years 2. Willing and able to comply with the study requirements 3. Willing and able to provide written informed consent to participate in the study Exclusion criteria: 1. Unable to complete the noninvasive procedure of VCET and CAP 2. Unwilling to provide written informed consent to participate in the study Laboratory tests and examinations: Baseline and two follow-up visits (every 6 months): 1. Blood pressure 2. BW, BH, waist circumference, BMI 3. Complete blood cell (CBC) count 4. Albumin, AST, ALT, alkaline phosphatase, total bilirubin, r-GT, uric acid, hsCRP 5. Sugar (fasting), HbA1c, insulin, HOMA-IR 6. DM lipid profiles, adiponectin, leptin 7. Liver ultrasound, FibroScan touch 520 8. FSH, Estrodiol (E2), LH 9. TSH, free T4 10. HBsAg, anti-HCV, HBV DNA, HCV RNA, HBsAg quantification, HBV genotype (if HBsAg or anti-HCV positive) 11. ANA, Anti-mitochondrial antibody 12. Review history of drug and menstruation cycles

NCT ID: NCT03486912 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

FALCON 2
Start date: June 12, 2018
Phase: Phase 2
Study type: Interventional

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage characterized by normal liver tissue being replaced by scar tissue).

NCT ID: NCT03486899 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

FALCON 1
Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

NCT ID: NCT03449446 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

ATLAS
Start date: March 21, 2018
Phase: Phase 2
Study type: Interventional

The primary objectives of this study are: - To assess the safety and tolerability of selonsertib (SEL), firsocostat (FIR) and cilofexor (CILO), administered alone or in combination, in participants with bridging fibrosis or compensated cirrhosis due to NASH - To evaluate changes in liver fibrosis, without worsening of NASH

NCT ID: NCT03445208 Completed - Liver Fibrosis Clinical Trials

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Start date: February 14, 2018
Phase: Phase 1
Study type: Interventional

This is a study of experimental medication BMS-986036 given to healthy participants.

NCT ID: NCT03439254 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

REVERSE
Start date: August 30, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

NCT ID: NCT03375008 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)

Start date: September 8, 2016
Phase: N/A
Study type: Interventional

1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH) 2. To develop non-invasive diagnosis tool using multiparametric Magnetic resonance(MR) imaging for nonalcoholic steatohepatitis(NASH)

NCT ID: NCT03332940 Completed - Clinical trials for Nonalcoholic Steatohepatitis

An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

Start date: December 6, 2017
Phase: Phase 1
Study type: Interventional

This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization to the liver in subjects with and without moderate to severe nonalcoholic steatohepatitis (NASH) by planar and SPECT/CT imaging. This study is designed to evaluate the safety and tolerability of Tc99m-tilmanocept in subjects with NASH.

NCT ID: NCT03329885 Terminated - Clinical trials for Rheumatoid Arthritis

A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

Start date: November 2, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to investigate experimental medication BMS-986251 taken by mouth in healthy patients and patients with average to very serious Psoriasis (a condition characterized by itchy, dry skin with a scaly rash).